The clinical content of preconception care: infectious diseases in preconception care

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 6 SUPPL. B, 2008, Pages

  Coonrod, Dean V ^a   Jack, Brian W ^b   Stubblefield, Phillip G ^b   Hollier, Lisa M ^c   Boggess, Kim A ^d   Cefalo, Robert ^d   Cox, Shanna N ^f   Dunlop, Anne L ^g   Hunter, Kam D ^a   Prasad, Mona R ^h   Lu, Michael C ⁱ   Conry, Jeanne A ^j   Gibbs, Ronald S ^k   Hogan, Vijaya K ^e  

^a MARICOPA MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e IL   (United States)

^f NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j University of Colorado Health Sciences Center Denver ^*  (United States)

^k UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

infectious disease; preconception; screening

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CLINDAMYCIN; ERYTHROMYCIN; GANCICLOVIR; ISONIAZID; MEFLOQUINE; METRONIDAZOLE; PEGINTERFERON; PENICILLIN G; PERMETHRIN; PRIMAQUINE; QUINOLONE DERIVATIVE; RIBAVIRIN; VIRUS RNA; ZIDOVUDINE;

ASYMPTOMATIC BACTERIURIA; BLOOD TRANSFUSION; CHLAMYDIASIS; CONGENITAL DISORDER; CORDOCENTESIS; CYTOMEGALOVIRUS INFECTION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA INFECTIOSUM; FETUS HYDROPS; GONORRHEA; GROUP B STREPTOCOCCAL INFECTION; HEALTH PROMOTION; HEMOLYTIC ANEMIA; HEPATITIS C; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION RISK; LISTERIOSIS; MALARIA; MATERNAL CARE; MONOTHERAPY; NEWBORN SEPSIS; PARVOVIRUS INFECTION; PERIODONTAL DISEASE; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS; PYELONEPHRITIS; REVIEW; RISK ASSESSMENT; RNA VIRUS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYPHILIS; TOXOPLASMOSIS; TREATMENT DURATION; TUBERCULOSIS; VAGINITIS; VIRUS TRANSMISSION;

BACTERIAL INFECTIONS; FEMALE; HUMANS; PARASITIC DISEASES; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; VIRUS DISEASES;

EID: 57149119254     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.08.062     Document Type: Review

References (120)

1. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep 50 (2001) 1-58
2. Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep RR-19 (2001) 59-85
3. Centers for Disease Control and Prevention (CDC). HIV testing among pregnant women: United States and Canada, 1998-2001. MMWR Morb Mortal Wkly Rep 51 (2002) 1013-1016
4. Kilby J.M. Human immunodeficiency disease: ACP PIER & AHFS DI essentials (2008), American College of Physicians, Philadelphia
5. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 study group. N Engl J Med 331 (1994) 1173-1180
6. Ioannidis J.P., Abrams E.J., Ammann A., et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 183 (2001) 539-545
7. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (2006), US Department of Health and Human Services, Rockville (MD)
8. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG committee opinion no.: 304, November 2004: prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 104 (2004) 1119-1124
9. Branson B.M., Handsfield H.H., Lampe M.A., et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 55 (2006) 1-17
10. Chou R, Huffman L. Screening for human immunodeficiency virus: focused update of a 2005 systematic evidence review for the U.S. preventive services task force. Prepared for the Agency for Healthcare Research and Quality by the Oregon Evidence-based Practice Center at the Oregon Health and Science University, Portland, Oregon, under Contract No. 290-02-0024, Task Order Number 1. AHRQ Publication No. 07-0597-EF-1. Rockville, MD: Agency for Healthcare Research and Quality. April 2007.
11. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 51 (2002) 1-38
12. Hawkins D., Blott M., Clayden P., et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Med 6 suppl (2005) 107-148
13. Reinus J.F., Leikin E.L., Alter H.J., et al. Failure to detect vertical transmission of hepatitis C virus. Ann Intern Med 117 (1992) 881-886
14. Moriya T., Sasaki F., Mizui M., et al. Transmission of hepatitis C virus from mothers to infants: its frequency and risk factors revisited. Biomed Pharmacother 49 (1995) 59-64
15. Bohman V.R., Stettler R.W., Little B.B., Wendel G.D., Sutor L.J., and Cunningham F.G. Seroprevalence and risk factors for hepatitis C virus antibody in pregnant women. Obstet Gynecol 80 (1992) 609-613
16. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
17. Zanetti A.R., Tanzi E., and Newell M.L. Mother-to-infant transmission of hepatitis C virus. J Hepatol 31 suppl (1999) 96-100
18. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 54 (2005) 1-47
19. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 60 (1982) 555-564
20. Jerant A.F., Bannon M., and Rittenhouse S. Identification and management of tuberculosis. Am Fam Physician 61 (2000) 2667-2678 2681-2
21. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49 (2000) 1-51
22. Wilson C.B., and Remington J.S. What can be done to prevent congenital toxoplasmosis?. Am J Obstet Gynecol 138 (1980) 357-363
23. Lopez A., Dietz V.J., Wilson M., Navin T.R., and Jones J.L. Preventing congenital toxoplasmosis. MMWR Recomm Rep 49 (2000) 59-68
24. Krick J.A., and Remington J.S. Toxoplasmosis in the adult: an overview. N Engl J Med 298 (1978) 550-553
25. Fuccillo D.A., Madden D.L., Tzan N., and Sever J.L. Difficulties associated with serological diagnosis of Toxoplasma gondii infections. Diagn Clin Immunol 5 (1987) 8-13
26. American College of Obstetricians and Gynecologists. ACOG practice bulletin: perinatal viral and parasitic infections (2000), The College, Washington (DC)
27. Preventing congenital toxoplasmosis. MMWR Morb Mortal Weekly Rep 49 (2000) 57-75
28. Stagno S., Pass R.F., Cloud G., et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256 (1986) 1904-1908
29. Nigro G., Adler S.P., La Torre R., and Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353 (2005) 1350-1362
30. Onorato I.M., Morens D.M., Martone W.J., and Stansfield S.K. Epidemiology of cytomegaloviral infections: recommendations for prevention and control. Rev Infect Dis 7 (1985) 479-497
31. Duff P. A thoughtful algorithm for the accurate diagnosis of primary CMV infection in pregnancy. Am J Obstet Gynecol 196 (2007) 196-197
32. Centers For Disease Control and Prevention. Cytomegalovirus (CMV): pregnancy. http://www.cdc.gov/cmv/pregnancy.htm Accessed on March 23, 2008
33. Siegman-Igra Y., Levin R., Weinberger M., et al. Listeria monocytogenes infection in Israel and review of cases worldwide. Emerg Infect Dis 8 (2002) 305-310
34. Varma J.K., Samuel M.C., Marcus R., et al. Listeria monocytogenes infection from foods prepared in a commercial establishment: a case-control study of potential sources of sporadic illness in the United States. Clin Infect Dis 44 (2007) 521-528
35. Gellin B.G., and Broome C.V. Listeriosis. JAMA 261 (1989) 1313-1320
36. Craig S., Permezel M., Doyle L., Mildenhall L., and Garland S. Perinatal infection with Listeria monocytogenes. Aust N Z J Obstet Gynaecol 36 (1996) 286-290
37. Ross D.S., Jones J.L., and Lynch M.F. Toxoplasmosis, cytomegalovirus, listeriosis, and preconception care. Matern Child Health J 10 (2006) S187-S191
38. Outbreak of listeriosis associated with homemade Mexican-style cheese: North Carolina, October 2000-January 2001. MMWR Morb Mortal Wkly Rep 50 (2001) 560-562
39. American College of Obstetricians and Gynecologists. ACOG patient education pamphlet AP001: nutrition during pregnancy (2007), The College, Washington (DC)
40. Rodis J.F., Hovick Jr. T.J., Quinn D.L., Rosengren S.S., and Tattersall P. Human parvovirus infection in pregnancy. Obstet Gynecol 72 (1988) 733-738
41. Rodis J.F., Quinn D.L., Gary Jr. G.W., et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 163 (1990) 1168-1171
42. Enders M., Weidner A., Zoellner I., Searle K., and Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 24 (2004) 513-518
43. Schild R.L., Bald R., Plath H., Eis-Hubinger A.M., Enders G., and Hansmann M. Intrauterine management of fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 13 (1999) 161-166
44. Rodis J.F., Borgida A.F., Wilson M., et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol 179 (1998) 985-988
45. Levy R., Weissman A., Blomberg G., and Hagay Z.J. Infection by parvovirus B 19 during pregnancy: a review. Obstet Gynecol Surv 52 (1997) 254-259
46. Rodis J.F., Rodner C., Hansen A.A., Borgida A.F., Deoliveira I., and Shulman Rosengren S. Long-term outcome of children following maternal human parvovirus B19 infection. Obstet Gynecol 91 (1998) 125-128
47. Nagel H.T., de Haan T.R., Vandenbussche F.P., Oepkes D., and Walther F.J. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 109 (2007) 42-47
48. Okoko B.J., Enwere G., and Ota M.O. The epidemiology and consequences of maternal malaria: a review of immunological basis. Acta Trop 87 (2003) 193-205
49. Desai M., ter Kuile F.O., Nosten F., et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7 (2007) 93-104
50. Centers for Disease Control and Prevention. Malaria during pregnancy. http://www.cdc.gov/malaria/pregnancy.htm Accessed March 23, 2008
51. Skarbinski J., James E.M., Causer L.M., et al. Malaria surveillance: United States, 2004. MMWR Surveill Summ 55 (2006) 23-37
52. Centers for Disease Control and Prevention. Malaria: diagnosis-microscopy. http://www.cdc.gov/malaria/diagnosis_treatment/microscopy.htm Accessed March 23, 2008
53. Centers for Disease Control and Prevention. Malaria: Diagnosis-rapid diagnostic test. http://www.cdc.gov/malaria/diagnosis_treatment/diagnosis_rdt.htm Accessed March 23, 2008
54. Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States. http://www.cdc.gov/malaria/pdf/treatmenttable.pdf Accessed March 23, 2008
55. Centers for Disease Control and Prevention. Malaria treatment guidelines. http://www.cdc.gov/malaria/pdf/clinicalguidance.pdf Accessed March 23, 2008
56. Menendez C., D'Alessandro U., and ter Kuile F.O. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 7 (2007) 126-135
57. Koren G., Matsui D., and Bailey B. DEET-based insect repellents: safety implications for children and pregnant and lactating women. CMAJ 169 (2003) 209-212
58. McGready R., Hamilton K.A., Simpson J.A., et al. Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. Am J Trop Med Hyg 65 (2001) 285-289
59. Gamble C., Ekwaru P.J., Garner P., and ter Kuile F.O. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomized controlled trials. PLoS Med 4 (2007) e107
60. Ward S.A., Sevene E.J., Hastings I.M., Nosten F., and McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 7 (2007) 136-144
61. Centers for Disease Control and Prevention. Preconception planning, pregnancy and travel. http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp?section=special&obj=pregnant.htm Accessed March 23, 2008
62. Greenwood B., Alonso P., ter Kuile F.O., Hill J., and Steketee R.W. Malaria in pregnancy: priorities for research. Lancet Infect Dis 7 (2007) 169-174
63. Centers for Disease Control and Prevention. Travelers' health: malaria. http://wwwn.cdc.gov/travel/contentMalariaDrugsHC.aspx Accessed March 24, 2008
64. Centers for Disease Control and Prevention. Travelers' health-information for health care providers: preventing malaria in the pregnant woman. http://wwwn.cdc.gov/travel/contentMalariaPregnantHC.aspx Accessed March 24, 2008
65. Centers for Disease Control and Prevention: Division of STD Prevention. STD surveillance 2006. http://www.cdc.gov/std/stats/Tables/Table1.htm Accessed March 24, 2008
66. US Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med 3 (2005) 263-267
67. Johnson R.E., Newhall W.J., Papp J.R., et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections: 2002. MMWR Recomm Rep 51 (2002) 1-38
68. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 (2006) 38-49
69. Updated recommended treatment regimens for gonococcal infections and associated conditions: United States, April 2007. MMWR Morb MortalWeekly Rep 56 (2007) 332-336
70. US Preventive Services Task Force. Screening for gonorrhea. http://www.ahrq.gov/clinic/uspstf/uspsgono.htm Accessed March 24, 2008
71. US Preventive Services Task Force. Screening for chlamydial infection: recommendations and rationale. Am J Prev Med 20 (2001) 90-94
72. US Preventive Services Task Force. Screening for chlamydial infection. http://www.ahrq.gov/clinic/uspstf/uspschlm.htm Accessed March 24, 2008
73. Nelson H.D., Glass N., Huffman L., Villemyer K., and Hamilton A. Screening for syphilis: a brief update for the US Preventive Services Task Force (2004), Agency for Healthcare Research and Quality, Rockville (MD)
74. US Preventive Services Task Force. Screening for syphilis (2004), Office of Disease Prevention and Health Promotion, Washington (DC)
75. Gupta R., Wald A., Krantz E., et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 190 (2004) 1374-1381
76. Corey L., Wald A., Patel R., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350 (2004) 11-20
77. Xu F., Sternberg M.R., Kottiri B.J., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296 (2006) 964-973
78. American College of Obstetricians and Gynecologists. ACOG practice bulletin. No.: 82: management of herpes in pregnancy (2000), The College, Washington (DC)
79. US Preventive Services Task Force. Screening for asymptomatic bacteriuria. http://www.ahrq.gov/clinic/uspstf/uspsbact.htm Accessed October 20, 2008
80. Offenbacher S., Lieff S., Boggess K.A., et al. Maternal periodontitis and prematurity: part I: obstetric outcome of prematurity and growth restriction. Ann Periodontol 6 (2001) 164-174
81. Jeffcoat M.K., Hauth J.C., Geurs N.C., et al. Periodontal disease and preterm birth: results of a pilot intervention study. J Periodontol 74 (2003) 1214-1218
82. Boggess K.A., Lieff S., Murtha A.P., Moss K., Beck J., and Offenbacher S. Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol 101 (2003) 227-231
83. Lopez N.J., Smith P.C., and Gutierrez J. Periodontal therapy may reduce the risk of preterm low birth weight in women with periodontal disease: a randomized controlled trial. J Periodontol 73 (2002) 911-924
84. Michalowicz B.S., Hodges J.S., DiAngelis A.J., et al. Treatment of periodontal disease and the risk of preterm birth. N Engl J Med 355 (2006) 1885-1894
85. American Academy of Periodontology Task Force on Periodontal Treatment of Pregnant Women. American Academy of Periodontology statement regarding periodontal management of the pregnant patient. J Periodontol 75 (2004) 495
86. Ismail A.I., Lewis D.W., and Dingle J.L. Prevention of periodontal disease. Canadian Guide to Clinical Preventive Health Care (1994), Health Canada, Ottawa
87. 2-producing lactobacilli, and bacterial vaginosis in pregnant women. Clin Infect Dis 16 suppl (1993) S273-S281
88. Lamont R.F., and Fisk N.M. The role of infection in the pathogenesis of preterm labour. vol 10. In: Studd J.W.W. (Ed). Progress in obstetrics and gynaecology (1993), Churchill Livingstone, London
89. Koumans E., Markowitz L.E., Hogan V., and CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis 35 suppl (2002) S152-S172
90. McGregor J.A., French J.I., Richter R., et al. Antenatal microbiologic and maternal risk factors associated with prematurity. Am J Obstet Gynecol 163 (1990) 1465-1473
91. Kurki T., Sivonen A., Renkonen O.V., Savia E., and Ylikorkala O. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 80 (1992) 173-177
92. Hillier S.L., Nugent R.P., Eschenbach D.A., et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant: the Vaginal Infections and Prematurity Study group. N Engl J Med 333 (1995) 1737-1742
93. Hay P.E., Lamont R.F., Taylor-Robinson D., Morgan D.J., Ison C., and Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ 308 (1994) 295-298
94. Leitich H., Bodner-Adler B., Brunbauer M., Kaider A., Egarter C., and Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 189 (2003) 139-147
95. Amsel R., Totten P.A., Spiegel C.A., Chen K.C., Eschenbach D., and Holmes K.K. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med 74 (1983) 14-22
96. Nugent R.P., Krohn M.A., and Hillier S.L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 29 (1991) 297-301
97. Hay P.E., Morgan D.J., Ison C.A., et al. A longitudinal study of bacterial vaginosis during pregnancy. BJOG 101 (1994) 1048-1053
98. Kiss H., Petricevic L., and Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 329 (2004) 371
99. Lamont R.F., Duncan S.L., Mandal D., and Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 101 (2003) 516-522
100. Guaschino S., Ricci E., Franchi M., et al. Treatment of asymptomatic bacterial vaginosis to prevent pre-term delivery: a randomised trial. Eur J Obstet Gynecol Reprod Biol 110 (2003) 149-152
101. Kekki M., Kurki T., Pelkonen J., Kurkinen-Raty M., Cacciatore B., and Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol 97 (2001) 643-648
102. Kurkinen-Raty M., Vuopala S., Koskela M., et al. A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis. BJOG 107 (2000) 1427-1432
103. Rosenstein I.J., Morgan D.J., Lamont R.F., et al. Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women. Infect Dis Obstet Gynecol 8 (2000) 158-165
104. Vermeulen G.M., and Bruinse H.W. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. BJOG 106 (1999) 652-657
105. McGregor J.A., French J.I., Jones W., et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 170 (1994) 1048-1060
106. Ugwumadu A., Manyonda I., Reid F., and Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 361 (2003) 983-988
107. McDonald H.M., Brocklehurst P., and Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev (2007) CD000262
108. Koumans EH, Lane SD, Aubry R, DeMott K, Berman S, Webster NJ. Evaluation of the BV component of Syracuse's Healthy Start Project. Abstract presented at MCH Epidemiology Conference at Centers for Disease Control and Prevention. Atlanta, GA, Dec. 6, 2006.
109. McGregor J.A., French J.I., Parker R., et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. Am J Obstet Gynecol 173 (1995) 157-167
110. Joesoef M.R., Hillier S.L., Wiknjosastro G., et al. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. Am J Obstet Gynecol 173 (1995) 1527-1531
111. United States Preventive Services Task Force. Screening for Bacterial vaginosis in pregnancy: recommendations and rationale. Internet Journal of Gynecology and Obstetrics (2002) 1. http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijgo/vol1n2/vaginosis.xml Available at: http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijgo/vol1n2/vaginosis.xml. Accessed March 1, 2008
112. American College of Obstetricians and Gynecologists. Practice bulletin no.: 31: assessment of risk factors for preterm birth: clinical management guidelines for obstetrician-gynecologists (2001), The College, Washington, DC
113. Hauth J.C., Goldenberg R.L., Andrews W.W., DuBard M.B., and Copper R.L. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 333 (1995) 1732-1736
114. Morales W.J., Schorr S., and Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 171 (1994) 345-349
115. Carey J.C., Klebanoff M.A., Hauth J.C., et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis: National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 342 (2000) 534-540
116. Larsson P.G., Bergstrom M., Forsum U., Jacobsson B., Strand A., and Wolner-Hanssen P. Bacterial vaginosis: transmission, role in genital tract infection and pregnancy outcome: an enigma. APMIS 113 (2005) 233-245
117. Centers for Disease Control and Prevention. Group B strep prevention: general public: frequently asked questions. http://www.cdc.gov/groupBstrep/general/gen_public_faq.htm Accessed March 24, 2008
118. Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report emerging infections program network group B streptococcus, 2006. http://www.cdc.gov/ncidod/dbmd/abcs/survreports/gbs06.pdf Accessed March 24, 2008
119. Prevention of perinatal group B streptococcal disease. MMWR Recomm Rep 51 (2002) 1-28
120. Regan J.A., Klebanoff M.A., Nugent R.P., et al. Colonization with group B streptococci in pregnancy and adverse outcome: VIP Study group. Am J Obstet Gynecol 174 (1996) 1354-1360